CD4 and HIV infectious disease: In participants with HIV infection and baseline CD4 T lymphocyte counts of at least 350 cells/mm3, intermittent subcutaneous IL-2 without concomitant antiretroviral therapy was well tolerated and produced significant increases in CD4 T lymphocyte counts and did not adversely affect plasma HIV RNA levels.